The Longevity Digest 02/17 - 02/23

I'm cutting through the noise in longevity and anti-aging podcasts so you don't have to.

Welcome to The Longevity Digest.

The field moves fast. Too fast for most of us to track every breakthrough, every protocol update, every researcher’s latest findings. That’s where this comes in.

I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.

Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.

This Newsletter Is Sponsored By Casa de Sante.

---

Dr Onyx MD PhD’s Insights on this week’s episodes

Your Mitochondria Are the New Vital Sign — And the Entire Field Is Converging on Why

The single loudest signal across this week’s longevity landscape isn’t a drug or a protocol — it’s a paradigm shift. Multiple independent conversations arrived at the same conclusion: mitochondrial function is the linchpin of aging, and nearly every organ system’s decline can be traced back to failing cellular energy.

On The Human Upgrade, the case was made that brain aging begins not with plaques or tangles, but with mitochondria that stop producing adequate ATP — and that low-dose methylene blue, a century-old compound, can act as an intracellular redox shuttle to restore that energy output (Ep. 1420). Separately, the same show explored an NAD+-first strategy using NMN paired with hydroxytyrosol and ergothioneine — not to simply push one pathway harder, but to simultaneously fuel the engine and cool the inflammation that accelerates its breakdown (Ep. 1417). Then Dr. Tony Wyss-Coray’s conversation on Huberman Lab tied the bow: exercise doesn’t just “help” the aging brain — it physically rewires the circulating proteome, releasing factors like clusterin and GPLD1 that transfer rejuvenation signals to sedentary tissue. His proteomic aging clocks now show that aging is organ-specific and measurable, with “age gaps” in muscle and brain predicting future disease years before symptoms surface.

The strategic takeaway is clear. The mitochondrion has graduated from a biology textbook sidebar to a clinical target. Whether you reach it through exercise-induced circulating factors, NAD+ precursors with anti-inflammatory co-factors, or even experimental redox modulators like methylene blue, the interventions converging this week share a common destination: restore cellular energy production, and the downstream benefits — cognition, metabolic fitness, inflammation control — follow.

What this means for practice: Mitochondrial health is no longer an abstract concept. It is becoming an actionable, measurable clinical variable. Proteomic clocks and organ-specific aging biomarkers (emerging through companies like Vero Biosciences, as discussed on Huberman Lab) will soon enable clinicians to quantify a patient’s cellular energy deficit and track whether interventions — pharmaceutical or lifestyle — are actually closing the gap.

---

This Newsletter Is Sponsored By Casa de Sante.

For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD Certified in Obesity Management, this Low FODMAP lineup supports nutrient absorption, muscle defense, and overall digestive balance:

• Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) – helps preserve lean muscle during weight loss

• FODMAP Digestive Enzymes – improves absorption and reduces GI side effects

• Advanced Probiotic + Prebiotic Synbiotic Formula – supports a balanced gut microbiome

• Essential Vitamin & Mineral Complex – replenishes nutrients often depleted during rapid weight loss

• Gentle Colon Cleanse + Probiotic Support – aids regular elimination without irritation

All formulas are low FODMAP, non-GMO, and third-party tested—the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.

Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin—especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:

• HydraLift Collagen Complex – firms and smooths for youthful elasticity

• Antioxidant C+E Ferulic Radiance Serum – brightens and defends against oxidative stress

• Needle-Free Wrinkle Smoother – softens fine lines without irritation

• Ultra Retinol 10x + Bakuchiol Serum – boosts cell turnover with gentle plant retinol

• Advanced Retinol Eye Repair – targets puffiness and under-eye wrinkles

• Cellular Repair Growth Factor Peptides Serum – rejuvenates and supports skin repair

• Advanced Neck Lift Firming Complex – improves tone and texture along the jawline and neck

• Even Tone Brightening Cream – evens discoloration for radiant, balanced skin

---

The Quiet War on Your Internal Ecosystem — From Gut to Glucose to Gums

A second theme threaded through this week’s episodes with surprising coherence: the environments inside and around your body are being systematically degraded — and the solutions are deceptively simple.

Microbiome Medics delivered one of the week’s most underappreciated warnings. The biocides embedded in everyday consumer products — antibacterial soaps, nanosilver textiles, chlorhexidine mouthwash — are not inert. Chlorhexidine disrupts the oral microbiome’s nitrate-to-nitrite-to-nitric-oxide pathway, a cascade that directly regulates blood pressure. Randomized trials show that routine chlorhexidine mouthwash raises systolic blood pressure — meaning a product marketed for oral “health” is quietly working against cardiovascular health. Meanwhile, the US FDA banned triclosan in hand washes years ago; the UK still has not, and broader regulatory gaps allow biocides to be marketed as consumer goods without rigorous benefit-harm evaluation.

This dovetails directly with the metabolic conversation. On The Second Opinion Podcast, Dr. Paul Kolodzik outlined how something as basic as the order you eat your food materially alters postprandial glucose curves — fiber first, then protein and fat, carbohydrates last. The resistant starch hack (cook, cool, reheat) converts ordinary starches into fiber-like substrates that blunt glycemic spikes. Health Longevity Secrets (Ep. 246) reinforced that glycemic control is not just a diabetes concern — sugar spikes and insulin resistance are directly linked to smaller hippocampal volumes and accelerated cognitive decline.

And then there’s The Human Upgrade‘s coverage (Ep. 1419) of microplastics detected in 100% of examined human testicular tissue — predominantly polyethylene and PVC — crossing the blood-testis barrier and provoking inflammation. Mouse models suggest paternal microplastic exposure may even program offspring toward insulin resistance, raising the specter of transgenerational metabolic harm.

The connective tissue: The body’s internal ecosystems — oral, gut, metabolic, reproductive — are under siege from modern chemical exposures and ultra-processed dietary patterns. The interventions, however, are low-tech and high-yield. Plain soap beats antibacterial soap. Food sequencing beats willpower. A two-week CGM trial reveals individualized glucose truths that no generic guideline can match. Clinicians who integrate these “boring” fundamentals into practice will deliver outsized patient impact.

Sleep, Structure, and the Toolbox That Actually Works

The third convergence across this week’s episodes is a practical one: the longevity field is maturing from “what to do” into “how to make it stick” — and the tools of adherence are getting sharper.

Docs Who Lift hosted a masterclass in what most clinicians get wrong about sleep. Melatonin is not a sedative. At the 5–10 mg doses many patients self-prescribe at bedtime, it is pharmacologically mismatched to the problem. The evidence supports 0.5–1 mg taken 4–6 hours before target bedtime — and only for circadian shifting (jet lag, delayed sleep phase), not chronic insomnia. For chronic insomnia, CBT-I remains the gold standard, yet it is vastly under-prescribed relative to medications. The episode also flagged an underdiagnosed population: perimenopausal women with obstructive sleep apnea, where symptoms may present atypically and get attributed to “hormonal changes.” Consumer wearables can support habit tracking, but their sleep staging data is imprecise enough to trigger “orthosomnia” — anxiety about sleep driven by the very device meant to improve it.

On the exercise side, Huberman Lab‘s conversation with Jeff Cavaliere introduced a low-cost recovery metric that every clinician can deploy immediately: morning handgrip dynamometry. A drop of 10% or more from personal baseline signals systemic under-recovery, and the prescription is simple — dial back intensity that day and reassess the next morning. The broader programming message was equally pragmatic: ~60% strength, ~40% conditioning, sessions under 60 minutes, and the best split is the one a patient will actually do consistently.

Hal Elrod’s updated Miracle Morning framework on The Human Upgrade (Ep. 1418) distilled behavior change into its most compressible form: six minutes covering silence, affirmations, visualization, exercise, reading, and scribing (SAVERS). Paired with a Miracle Evening protocol — no caloric intake 3–4 hours before bed, blue-light restriction in the final hour — this is a circadian-aligned behavioral scaffold that requires almost no equipment, no cost, and no specific wake time.

The clinical implication: The field’s most impactful tools right now are not exotic compounds or expensive diagnostics. They are structured routines, correct dosing of existing interventions (melatonin, exercise load), simple biomarkers (handgrip, CGM), and evidence-based behavioral frameworks. The longevity conversation is shifting from molecular excitement to implementation science — and the practitioners who master adherence architecture will outperform those chasing the next molecule.

This weeks episodes:

1. Health Longevity Secrets

246- Why Your Brain Doesn’t Have to Age

Published: 2026-02-17

URL: Listen Here

Summary

This episode argues that age-related cognitive decline is largely preventable and often reversible by targeting modifiable factors with a structured, personalized lifestyle program. Emphasizing exercise as the highest-yield lever, the discussion outlines a five-pillar approach that improves brain physiology and performance, reframes Alzheimer’s risk, and highlights the roles of metabolic health, purpose, stress control, and continuous learning in sustaining cognition.

Key Takeaways

• Cognitive decline with aging is common but not biologically ‘normal’; many causes are modifiable and reversible when addressed systematically.

• The brain is an organ with cellular needs (oxygen, ATP, nutrients) and high plasticity—especially in the hippocampus—so targeted lifestyle changes can improve function within about 12 weeks.

• A five-pillar framework (exercise, sleep, nutrition, stress reduction, and ongoing cognitive challenge) increases cerebral blood flow, lowers inflammation, enhances waste clearance, and reduces pathological proteins.

• Glycemic control is critical: sugar spikes, insulin resistance, and obesity are linked to smaller hippocampal volumes and worse cognition; prioritize low-glycemic, minimally processed foods and avoid added sugars.

• Purpose in life, stress management, and allowing ‘boredom’/mind-wandering support creativity, resilience, and are associated with lower risks of stroke, heart disease, and dementia.

Clinical Insight

In patients with subjective memory concerns or mild cognitive impairment, a personalized program addressing reversible contributors (sleep apnea, depression, polypharmacy, metabolic risk, inactivity, poor sleep and diet) and implementing the five brain-health pillars can yield rapid, clinically meaningful gains—often normalizing performance on screening (e.g., MoCA) within approximately 12 weeks.

Actionable Takeaway

For adults with memory complaints, conduct a focused evaluation for reversible factors (sleep apnea screening, depression assessment, medication review, metabolic labs including HbA1c) and prescribe a 12-week plan prioritizing: aerobic activity most days plus 2 days/week of resistance training; 7–8 hours of high-quality sleep; elimination of added sugars and refined carbs in favor of low-glycemic whole foods; daily stress-reduction practice; and engagement in a challenging new learning activity.

2. The Human Upgrade: Biohacking for Longevity & Performance

The Secret to Looking Younger is in Mushrooms (And Chocolate?) : 1417

Published: 2026-02-17

URL: Listen Here

Summary

This episode focuses on optimizing mitochondrial function and healthy aging by elevating NAD+ with NMN and supporting redox/inflammatory balance using hydroxytyrosol and ergothioneine. The hosts discuss mechanistic rationale, regulatory context, real-world benefits (energy, sleep, cognition, hair), women’s health/fertility considerations, and practicalities (oral vs. IV NAD+, methyl donors, allulose-based formulations). Some claims are preliminary or anecdotal and specific trials/doses are not always cited; minor transcript redactions were noted.

Key Takeaways

• Oral NAD+ repletion using precursors (NMN or NR) improves energy, cognition, and sleep; NMN may have an uptake advantage via a cell-surface transporter and, when paired with anti-inflammatory co-factors, can be more effective and better tolerated than NAD+ IVs.

• Combining NMN with hydroxytyrosol (olive polyphenol) and ergothioneine (mushroom-derived antioxidant) may offset CD38-driven NAD+ consumption and systemic inflammation, offering a synergistic, mitochondria-supportive stack.

• Anecdotal user reports include cosmetic changes (thicker hair, reduced graying, eyelash/eyebrow regrowth) and women’s health benefits (fertility support, improved peri/post-menopausal symptoms), though controlled clinical confirmation is pending.

• If NAD+ IVs are used, pre-dosing methyl donors (e.g., trimethylglycine) can reduce adverse infusion symptoms; however, well-formulated oral precursors are generally sufficient for most patients.

• Adjunct innovations discussed include metabolically friendly sweetening with allulose (which does not spike glucose and may raise GLP-1), creatine delivered in high-quality chocolate for better uptake, and low-waste packaging—practical considerations for long-term adherence.

Clinical Insight

A combination strategy that raises NAD+ (via NMN) while simultaneously tempering inflammation and oxidative stress (via hydroxytyrosol and ergothioneine) appears to provide broader, more sustainable clinical benefits than NAD+ monotherapy—particularly relevant for midlife patients with fatigue, cognitive slowing, or metabolic stress.

Actionable Takeaway

Trial an 8–12 week oral regimen pairing an NAD+ precursor (e.g., NMN) with antioxidant co-factors (hydroxytyrosol and ergothioneine), tracking patient-reported outcomes (energy, focus, sleep) and basic labs as indicated; if a patient receives NAD+ IVs, pre-dose 1–2 g trimethylglycine (TMG) to improve tolerability.

3. Microbiome Medics

Killing 99.9% of the Wrong Things: The Hidden Cost of Disinfectants

Published: 2026-02-18

URL: Listen Here

Summary

This episode examines the hidden costs of ubiquitous biocides in consumer products—linking regulatory gaps to microbiome disruption, antimicrobial resistance, and environmental harm—and outlines a UK bill to curb unnecessary biocidal additives. It underscores evidence that plain soap is as effective as antibacterial soaps for community use and that chlorhexidine mouthwash can adversely affect cardiovascular physiology via the oral microbiome, while emphasizing precautionary, system-level solutions alongside maintaining essential medical disinfection.

Key Takeaways

• A UK Private Members’ Bill (Consumer Products – Control of Biocides) seeks to restrict deliberate addition of biocides to consumer products unless demonstrable benefits outweigh harms, targeting antimicrobial resistance, microbiotoxicity, and environmental impacts.

• Many consumer biocides (e.g., disinfectants, antiseptics, nanosilver-treated textiles) are regulated as consumer goods rather than medicines, enabling marketing-driven use without strong evidence of added benefit in community settings.

• Evidence indicates antibacterial soaps are no more effective than plain soap and water for community use; the US FDA has banned triclosan in OTC hand washes, while the UK has not.

• Chlorhexidine mouthwash can disrupt the oral microbiome, reduce nitrate–nitrite–NO bioavailability, lower salivary pH/buffering, and raise systolic blood pressure in randomized trials—highlighting nontrivial systemic effects from routine use.

• Excessive biocide use selects for resistance genes and contributes to environmental ‘cocktail effects’ (e.g., with PFAS, microplastics); precautionary, system-level regulation is needed while preserving essential medical disinfection in clinical settings.

Clinical Insight

Routine use of consumer biocides offers no proven infection-prevention advantage in community settings and can harm human microbiomes, drive antimicrobial resistance, and even raise blood pressure via oral NO pathway disruption—so potent biocides should be reserved for clear, short-term clinical indications.

Actionable Takeaway

Advise patients to use plain soap and water for hand hygiene and avoid routine antibacterial soaps and mouthwashes; reserve chlorhexidine for short-term, specific dental indications and choose personal-care products without triclosan/triclocarban, chlorhexidine, or nanosilver where feasible.

4. The Second Opinion Podcast with Dr. Paul Kolodzik

EP 108 The Order of Eating: How Food Sequencing Affects Your Health with Dr. Paul Kolodzik

Published: 2026-02-19

URL: Listen Here

Summary

This episode explains how food sequencing, strategic carb pairing, and the cooled-then-reheated starch ‘resistant starch’ hack can flatten post-meal glucose curves, potentially improving energy and metabolic health. The hosts also advocate brief CGM use for individualized insights and note that time above ~140 mg/dL may promote vascular inflammation. Discussion was conversational and did not cite specific primary studies.

Key Takeaways

• Sequencing meals—fiber-rich vegetables first, then protein with fat, and carbohydrates last—can blunt postprandial glucose spikes and reduce reactive hypoglycemia symptoms.

• Pairing carbohydrates with protein and/or fat (“put clothes on your carbs”) slows absorption and lowers glucose excursions (e.g., apple with cheese, toast with egg/avocado, banana with unsweetened peanut butter).

• Cooling then reheating cooked starches (e.g., potatoes, pasta) increases resistant starch (RS3), which acts more like fiber and reduces glycemic impact versus freshly cooked versions.

• Aim to minimize time above ~140 mg/dL glucose to limit potential endothelial inflammation; flatter glucose curves are preferable to sharp spikes and crashes.

• Short-term continuous glucose monitor (CGM) use (e.g., a two-week trial) provides personalized feedback that often drives meaningful dietary behavior change.

Clinical Insight

The order in which macronutrients and fiber are consumed materially alters postprandial glycemia; structuring meals as fiber → protein/fat → carbohydrates is a simple, scalable intervention to improve glucose stability and metabolic health.

Actionable Takeaway

For the next week, at each mixed meal eat non-starchy vegetables or salad first, then the protein (with its accompanying fats), and save starches/sugary carbohydrates for last to reduce glucose spikes.

5. Huberman Lab

Essentials: Optimize Your Exercise Program with Science-Based Tools | Jeff Cavaliere

Published: 2026-02-19

URL: Listen Here

Summary

This episode distills practical, evidence-informed training principles: prioritize adherence-friendly programming, place cardio after weights, cultivate mind–muscle connection for hypertrophy, monitor recovery with simple tools like handgrip strength, and safeguard joint health through sound biomechanics and smart stretching. The guidance emphasizes sustainability and performance while reducing injury risk—directly applicable to general and athletic populations.

Key Takeaways

• A sustainable weekly structure is ~60% strength and ~40% conditioning (e.g., 3 strength days and 2 conditioning days), with sessions kept under ~60 minutes and warm-ups made more thorough with age; choose a split you will adhere to (full-body, push–pull–legs, or even “bro” splits can all work).

• Pair cardio with lifting on the same day only after resistance training to avoid performance interference; blend conditioning with functional drills (HIIT, ladders, line drills, burpees) to increase engagement and deliver crossover benefits.

• Deliberate mind–muscle connection (“cramp test”) improves hypertrophy and muscular ‘tone’; seek targeted, tolerable discomfort in the working muscle and practice consistently to improve neural recruitment.

• Use soreness to guide local (muscle-level) recovery, and track systemic recovery with handgrip output; a ~10% or greater drop from baseline suggests you should reduce intensity or rest that day.

• Protect joint mechanics: avoid upright rows (internal rotation with elevation) and substitute high pulls (hands higher than elbows) to maintain external rotation; regularly train external rotators (shoulder/hip); grip the bar in the meat of the palm (not fingertips) to reduce medial epicondylitis risk; do dynamic stretching before and passive stretching away from workouts (e.g., evening).

Clinical Insight

Simple, low-cost morning handgrip testing can serve as a practical proxy for systemic fatigue/under-recovery; a ~10% drop from personal baseline is a useful threshold to adjust training load and reduce injury risk.

Actionable Takeaway

Have patients perform a brief daily maximal handgrip test (bathroom scale or dynamometer) upon waking; if grip strength is ≥10% below their baseline, replace heavy/intense work with recovery or light technique work that day and reassess the following morning.

6. The Human Upgrade: Biohacking for Longevity & Performance

Change Your Morning, Change Your Life – Hal Elrod : 1418

Published: 2026-02-19

URL: Listen Here

Summary

Hal Elrod shares the updated Miracle Morning and a new Miracle Evening, highlighting adaptable behavior-change tools (SAVERS, Emotional Optimization Meditation, sleep hygiene) that align with circadian biology and can fit any schedule. He details his ALL experience—choosing urgent chemotherapy while adding complementary practices—and emphasizes rigorous patient self‑advocacy and integrative care. For clinicians, the episode underscores how brief, structured routines may improve stress, sleep, and adherence; most claims are anecdotal, with few formal citations provided.

Key Takeaways

• Hal Elrod presents an updated Miracle Morning (SAVERS: Silence, Affirmations, Visualization, Exercise, Reading, Scribing) and a new Miracle Evening framework focused on sleep hygiene (e.g., stop eating 3–4 hours before bed, limit blue light, calming affirmations, brief reading, optional natural sleep aids).

• The routines are intentionally flexible: they need not start at 5 a.m., can be condensed to as little as six minutes, and can be adapted to chronotype, shift work, postpartum schedules, and health status.

• Elrod introduces Emotional Optimization Meditation—selecting and installing an optimal state (e.g., bliss, confidence, love) each morning—and reframes affirmations to emphasize commitment, reasons (why), and concrete actions with timing.

• Cancer narrative: after diagnosis of acute lymphoblastic leukemia (ALL) with organ compromise and a 20–30% survival estimate, Elrod pursued immediate chemotherapy (aligned with advice from both conventional and holistic oncologists) while adding complementary practices (e.g., acupuncture, lymphatic massage, ozone sauna, coffee enemas, supplements); he stresses strong patient self-advocacy.

• Behavior and circadian strategies discussed include habit/accountability apps, calendarizing tasks to reduce rumination, blue‑light restriction in the hour before bed, and cautious nutrition commentary noting many tumors’ sensitivity to glucose/insulin and the importance of individualized dietary guidance during treatment.

Clinical Insight

Simple, structured morning and evening routines that combine emotion regulation, brief exercise/meditation, and circadian-aligned sleep hygiene can bolster patient energy, stress management, adherence, and treatment tolerance—especially in chronic disease and cancer—when layered alongside evidence‑based medical care.

Actionable Takeaway

Consider prescribing a brief ‘6‑minute SAVERS’ (1 minute each of silence, affirmations with commitment/why/action, visualization, light exercise, reading, and scribing) plus sleep hygiene (no caloric intake 3–4 hours before bed and blue‑light blocking for the final 60 minutes), and reassess sleep, fatigue, and stress at follow‑up.

7. The Human Upgrade: Biohacking for Longevity & Performance

Plastic in Your Testicles, AI Sleep Scans, The 29% Weight Loss Drug : 1419

Published: 2026-02-20

URL: Listen Here

Summary

This episode surveys emerging levers and hidden risks shaping longevity: microplastics in testes with endocrine and potential transgenerational effects, mindset-linked epigenetic aging, and a triple-agonist producing near-bariatric weight loss that requires muscle-sparing protocols. It spotlights AI sleep analytics that forecast multi-disease risk from one night of data and hypoxia-driven erythrocyte rewiring that may inform novel antidiabetic therapies. A pending U.S. bill on supplement regulation could reshape access to longevity compounds, underscoring the need for evidence-based adoption alongside fundamentals.

Key Takeaways

• Microplastics were detected in 100% of examined human testicular samples (predominantly polyethylene and PVC), crossing the blood–testis barrier, provoking inflammation/oxidative stress, and potentially impairing testosterone and sperm quality; mouse data suggest paternal exposure may program offspring toward insulin resistance.

• Negative beliefs and anxiety about aging correlated with epigenetic age acceleration on DNA methylation clocks, implicating stress/inflammatory pathways and positioning mindset as a measurable input to biological aging.

• Retatrutide (a triple GLP-1/GIP/glucagon agonist) produced ~24–29% average weight loss in a 68-week phase II trial—magnitudes approaching bariatric outcomes—highlighting the need for protocols to preserve lean mass and prevent rebound.

• An AI model from Stanford (SleepFM), trained on ~585,000 hours of polysomnography, predicted risk for 130 conditions from a single night of sleep (C-index ~0.84 for all-cause mortality; ~0.85 for dementia), framing sleep architecture as a dense systemic aging biomarker.

• Hypoxia at altitude rewires red blood cell metabolism into “glucose sponges,” lowering circulating glucose; a first-in-animal compound mimicked this pathway, suggesting a new therapeutic axis beyond GLP-1s/metformin and supporting hypoxic training as a metabolic tool.

Clinical Insight

Potent incretin-based anti-obesity therapies (e.g., retatrutide) can deliver unprecedented weight loss but must be embedded in a structured protocol that prioritizes lean mass preservation, adequate protein intake, resistance training, and a defined maintenance/off‑ramp plan to avoid sarcopenia and weight regain.

Actionable Takeaway

If prescribing a GLP‑1/GIP/glucagon agonist, implement a muscle-preservation protocol: target protein ≥1.2 g/kg/day, schedule resistance training 2–3 times/week, monitor body composition (DEXA/BIA), and establish a maintenance/off‑ramp plan before dose escalation.

8. This Week in Cardiology

Feb 20 2026 This Week in Cardiology

Published: 2026-02-20

URL: Listen Here

Summary

This episode centers on evolving long-term evidence in low-risk severe AS, highlighting higher late reintervention and concerning mortality/stroke signals with self-expanding TAVR compared with SAVR, reinforcing a cautious approach to TAVR in younger, low-risk patients. It also covers ethics and documentation for unilateral DNR orders, confirms lack of benefit from targeted hypothermia at 2 years post–cardiac arrest, praises a sham-controlled HFpEF shunt trial design, and notes hypothesis-generating data that GLP-1 therapy may improve AF ablation outcomes via weight loss.

Key Takeaways

• Evolut Low Risk TAVR vs SAVR at 6–7 years: no statistically significant difference in death/disabling stroke, but higher late reintervention with self-expanding TAVR (≈9.8% vs 6.0% at 7 years) and numerically higher late all-cause mortality; curve crossing suggests non-proportional hazards and potential late disadvantage for TAVR.

• Reinterventions after TAVR are clinically serious (often requiring surgery); more TAVR reinterventions were driven by aortic insufficiency, while stenosis-related reinterventions were similar between groups.

• Synthesis of longer-term evidence increasingly favors SAVR in low-/intermediate-risk patients: a Heart (BMJ) meta-analysis shows higher 5-year mortality with TAVR; UK TAVI 5-year data (conference) reported higher stroke with TAVR; a contrasting JACC meta-analysis appears influenced by shorter follow-up weighting.

• JAMA viewpoint highlights the ethics and documentation gap around unilateral DNR orders; authors call for a distinct EHR order type with explicit notation of disagreement and requirements to reassess code status as the clinical state improves.

• Critical care and rhythm management updates: TTM2 2-year follow-up confirms no neurologic benefit from targeted hypothermia vs active normothermia/fever prevention; sham-controlled design in the Alt-Flow-2 HFpEF shunt trial is exemplary; observational Europace study links semaglutide initiation around AF ablation to lower AF recurrence, plausibly via weight loss (hypothesis-generating).

Clinical Insight

For younger, low-surgical-risk patients with severe aortic stenosis, accumulating mid-to-long-term data—especially with self-expanding TAVR—suggests higher late reintervention and possible disadvantages in mortality and stroke, arguing for careful shared decision-making and a lower threshold to favor SAVR when durability is paramount.

Actionable Takeaway

When counseling low-risk severe AS patients (especially <75 years), explicitly review 5–7-year outcomes (higher late reintervention with Evolut TAVR and numerically higher mortality/stroke) and document shared decision-making; default to SAVR when long-term durability and neurologic outcomes are prioritized until robust, long-term data with newer TAVR iterations are available.

9. The Human Upgrade: Biohacking for Longevity & Performance

I Tested The Most Dangerous Viral Brain Hack : 1420

Published: 2026-02-22

URL: Listen Here

Summary

This episode argues that mitochondrial dysfunction underlies early brain aging and positions low-dose methylene blue, alongside circadian, sleep, diet, and environmental interventions, as a strategy to restore cellular energy and cognitive performance. It highlights dosing precision, product quality, storage, and major interaction risks as critical for safe use in practice.

Key Takeaways

• Brain aging and cognitive decline are framed as beginning with mitochondrial dysfunction; poor sleep, circadian disruption, indoor pollutants (e.g., mold), and dietary factors accelerate this process.

• Methylene blue is presented as a century-old compound that can act as an intracellular redox shuttle and antioxidant, enhance mitochondrial ATP production, cross the blood–brain barrier, and potentially stabilize amyloid proteins.

• Safety is dose-dependent: low doses may reduce oxidative stress, while high doses can become pro-oxidant; only medical/research-grade methylene blue should be used (not aquarium/industrial grade), and it must be stored away from heat and light.

• Drug interactions are a key concern: at higher doses methylene blue has MAOI/SSRI-like activity and may interact with antidepressants or serotonergic agents (including psychedelics), with a theoretical risk of serotonin-related adverse reactions.

• Suggested use emphasizes low starting doses (about 5–15 mg), intermittent cycling (days on, days off), monitoring subjective outcomes (clarity, focus, sleep resilience), and pairing with lifestyle levers (morning light, reduced evening light, anti-inflammatory diet, breathwork, air quality management, sauna/sweating).

Clinical Insight

Low-dose, medical-grade methylene blue may serve as an off-label redox modulator to support mitochondrial function and cognitive resilience, but its clinical use requires careful attention to dose, product purity, storage, and stringent screening for serotonergic drug interactions.

Actionable Takeaway

If considering methylene blue for patients with fatigue or brain fog, first perform a thorough medication review for serotonergic or MAOI-active agents, then—if appropriate—initiate a low-dose trial (e.g., 5–15 mg, intermittently cycled), using medical/research-grade product stored cool and dark, and track cognition, mood stability, sleep resilience, and any adverse effects.

10. Huberman Lab

Restore Youthfulness & Vitality to the Aging Brain & Body | Dr. Tony Wyss-Coray

Published: 2026-02-23

URL: Listen Here

Summary

This episode details how blood-borne factors regulate aging across organs and cells, emphasizing preclinical findings that young blood and exercise‑modified plasma rejuvenate the aging brain, and early human signals from therapeutic plasma exchange in Alzheimer’s disease. It introduces proteomic aging clocks that reveal organ/cell-specific ‘age gaps’ predictive of disease and underscores that lifestyle (exercise, sleep, sunlight, social connection) currently offers the most robust, practical means to preserve healthspan, whereas many supplements lack clinical proof. Note: portions of the transcript were truncated, so certain details may be incomplete.

Key Takeaways

• Young systemic factors can rejuvenate the aging brain: in mice, heterochronic parabiosis and select plasma fractions reduce neuroinflammation, reactivate neural stem cells, and improve memory; early human studies (e.g., therapeutic plasma exchange with albumin; small plasma-fraction trials) show promising cognitive signals and modest epigenetic clock shifts but require larger RCTs.

• Blood is a regulator, not just a readout: the circulating proteome changes markedly with age and carries both pro-aging inflammatory signals and pro-youth growth factors; exercise and caloric restriction remodel plasma, and exercise-induced blood factors (e.g., clusterin, GPLD1) can transfer brain benefits to sedentary/older animals.

• Aging is organ- and cell-type specific: proteomic ‘clocks’ reveal waves of aging (notably mid-30s and ~60s) and organ age-gaps that predict future disease; newer cell-level clocks link ‘old’ skeletal/cardiac muscle signatures to ALS risk and astrocyte age to Alzheimer’s risk; clinical tools (e.g., Vero Biosciences) are emerging to measure and track this biology.

• No supplement or drug (e.g., NAD/NMN) has proven to extend human lifespan/healthspan; product quality is variable. In contrast, lifestyle pillars—regular exercise (including resistance and some high intensity), sufficient sunlight, quality sleep, nutritious diet, and social connection—have the strongest human evidence for preserving cognitive and systemic function.

• Interventions landscape: PRP is FDA‑cleared for certain musculoskeletal uses; exosomes and stem‑cell injections remain experimental with safety/quality variability; fasting shows mechanistic benefits in animals but mixed human data—personalization and clinical oversight are essential.

Clinical Insight

Quantifying organ- and cell-type–specific aging from blood proteomics (and the resulting ‘age gaps’) enables clinically meaningful risk stratification for future organ disease and provides a biomarker framework to monitor interventions; paired with convergent preclinical and early clinical evidence that modifying the circulating milieu (e.g., via exercise-induced factors or plasma exchange/fractions) can improve brain function, this shifts practice toward preserving healthspan rather than focusing solely on lifespan.

Actionable Takeaway

Advise patients to follow a structured exercise program—150–300 minutes/week of moderate aerobic activity (or 75–150 minutes vigorous) plus ≥2 resistance sessions weekly, with 1–2 short high‑intensity interval bouts—to harness exercise‑induced circulating factors (e.g., clusterin, GPLD1) that support brain and systemic health, while also improving sleep and metabolic function.

11. Docs Who Lift

Top Sleep Doctor: Stop Taking Melatonin Like This

Published: 2026-02-23

URL: Listen Here

Summary

This episode reviews evidence-based management of insomnia and sleep health with emphasis on behavioral sleep medicine. Key themes include correct melatonin use (low-dose, early timing for circadian shifts), the central role of CBT-I over medications for chronic insomnia, the importance of consistent sleep-wake schedules, and careful screening for comorbidities such as OSA in perimenopausal women. The discussion also clarifies limitations of antihistamines and consumer wearables for sleep and outlines judicious roles for newer pharmacologic options when needed.

Key Takeaways

• CBT-I (cognitive behavioral therapy for insomnia) is the gold-standard, first-line treatment for chronic insomnia; sleep hygiene alone rarely resolves persistent sleep problems.

• Melatonin is best used as a circadian shifter (e.g., jet lag, delayed sleep phase) at low doses (0.5–1 mg) taken several hours before bedtime, not as a high-dose sedative at bedtime for insomnia.

• Consistency of sleep-wake timing (within ~30–60 minutes day-to-day) is foundational and often more impactful than chasing an exact “8 hours”; most adults do well with 6–9 hours alongside good sleep hygiene (limited late caffeine/alcohol, light exercise timing, cool/dark/quiet rooms, and mindful screen/content use).

• Assess and address common comorbid contributors to sleep disturbance—including OSA (often under-recognized in perimenopausal women), anxiety/depression, chronic pain, PCOS, medications—before escalating sedatives; avoid routine antihistamines due to limited efficacy and anticholinergic risks.

• Wearables (e.g., rings/watches) can support general habits and duration estimates but are not sleep studies; staging data are imperfect and may worsen insomnia via hyperfocus (”orthosomnia”).

Clinical Insight

For chronic insomnia, prioritize CBT-I with time-in-bed restriction and stimulus control—and evaluate for circadian misalignment and obstructive sleep apnea (especially in perimenopausal women)—before prescribing or escalating pharmacologic sleep aids; use melatonin only in low doses, timed hours before bed, for circadian indications.

Actionable Takeaway

If a patient is taking 5–10 mg melatonin at bedtime for insomnia, deprescribe that approach and, when delayed sleep phase is suspected, re-time to 0.5–1 mg taken 4–6 hours before target bedtime while standardizing a fixed morning wake time; otherwise, refer for CBT-I.

Stay connected with Dr Onyx MD PhD for clinical insights and wellness tools that bridge science and everyday care:

Instagram ✦ X (Twitter) ✦ LinkedIn ✦ Website

From Insights to Action

Knowledge without execution changes nothing. The insights above only reach their full potential when integrated into a strategic, personalized plan. That’s where two offerings come in:

---

Personalized Medical AI Chatbot

Healthcare complexity is overwhelming. Clinical studies, conflicting guidelines, and fragmented records leave most patients paralyzed.

Deploy your Dr Onyx MD PhD Medical AI Chatbot—a personalized architecture that synthesizes your medical history, the latest research, and your unique condition into clear, actionable insights.

It’s not a replacement for your doctors—it’s your secret weapon for making better decisions and becoming the CEO of your own care.

👉 Deploy your Medical AI Chatbot today and take control of your health narrative

Premium Longevity Program

For people who know their most valuable asset is their health.

This year-long partnership delivers clarity, accountability, and physician-led execution. Stop collecting fragmented data and start acting on a ranked, strategic plan tailored to your biology and lifestyle.

👉 Discover the Premium Longevity Program and secure your health as your ultimate investment.